Literature DB >> 10982151

Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines.

A M Donson1, A Banerjee, F Gamboni-Robertson, J M Fleitz, N K Foreman.   

Abstract

Previous studies have confirmed that proliferation in glioblastoma cell lines can be blocked by non-isoform specific protein kinase C (PKC) inhibitors, e.g calphostin C, staurosporine. However, the exact mechanism of PKC involvement is poorly understood. The aim of this study was to explore the role of specific PKC isoforms in the aberrant growth of glioblastoma. Identification of the isoform(s) critical for proliferation in glioblastoma would present a better target for the design of chemotherapeutic strategies. To this end, we screened expression on PKC isoforms in four human glioblastoma cell lines both when proliferating and in a quiescent state using western assays. PKC isoforms alpha, beta, betaII and zeta were found to be expressed in all cell lines. PKC epsilon was detected in three out of four cell lines and PKC eta was detected in one out of four cell lines. Quiescence of growth resulted in down-regulation of PKC epsilon. We examined the role of these isoforms by studying the effect of PKC isoform-specific inhibitors bisindolylmaleimide-I and Gö6976 on proliferation in a panel of four human glioblastoma cell lines. Inhibition of PKC alpha and epsilon had no effect on proliferation, suggesting that previous studies targeting PKC alpha may not be of therapeutic benefit. More significantly, it was shown that inhibition of PKC zeta blocked proliferation. This suggests that the inhibition of PKC zeta may be an important chemotherapeutic target for arresting growth in glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982151     DOI: 10.1023/a:1006406208376

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro.

Authors:  I F Pollack; S Kawecki
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

2.  Protein kinase C zeta isoform is critical for mitogenic signal transduction.

Authors:  E Berra; M T Diaz-Meco; I Dominguez; M M Municio; L Sanz; J Lozano; R S Chapkin; J Moscat
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

Review 3.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

4.  Differential expression of Rho family GTP-binding proteins and protein kinase C isozymes during C6 glial cell differentiation.

Authors:  S Yoshimura; H Sakai; S Nakashima; Y Nozawa; J Shinoda; N Sakai; H Yamada
Journal:  Brain Res Mol Brain Res       Date:  1997-04

5.  Protein expression of the alpha, gamma, delta and epsilon subspecies of protein kinase C changes as C6 glioma cells become contact inhibited and quiescent in the presence of serum.

Authors:  K Moreton; R Turner; N Blake; A Paton; N Groome; M Rumsby
Journal:  FEBS Lett       Date:  1995-09-18       Impact factor: 4.124

6.  Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.

Authors:  M Hermansson; M Nistér; C Betsholtz; C H Heldin; B Westermark; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts.

Authors:  A M Cacace; S N Guadagno; R S Krauss; D Fabbro; I B Weinstein
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

8.  Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro.

Authors:  W T Couldwell; J H Uhm; J P Antel; V W Yong
Journal:  Neurosurgery       Date:  1991-12       Impact factor: 4.654

9.  Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen.

Authors:  W T Couldwell; M H Weiss; C M DeGiorgio; L P Weiner; D R Hinton; G R Ehresmann; P S Conti; M L Apuzzo
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

10.  Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.

Authors:  M Bredel; I F Pollack; J M Freund; A D Hamilton; S M Sebti
Journal:  Neurosurgery       Date:  1998-07       Impact factor: 4.654

View more
  12 in total

1.  Effects of the PKC inhibitor PD 406976 on cell cycle progression, proliferation, PKC isozymes and apoptosis in glioma and SVG-transformed glial cells.

Authors:  C Russell; M Acevedo-Duncan
Journal:  Cell Prolif       Date:  2005-04       Impact factor: 6.831

2.  Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.

Authors:  Nicholas Butowski; Susan M Chang; Kathleen R Lamborn; Mei Yin Polley; R Parvataneni; Maria Hristova-Kazmierski; Luna Musib; Steven J Nicol; Donald E Thornton; Michael D Prados
Journal:  Neuro Oncol       Date:  2010-02-15       Impact factor: 12.300

3.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Regulation of glioma cell migration by serine-phosphorylated P311.

Authors:  Wendy S McDonough; Nhan L Tran; Michael E Berens
Journal:  Neoplasia       Date:  2005-09       Impact factor: 5.715

5.  Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.

Authors:  Nicholas Butowski; Susan M Chang; Kathleen R Lamborn; Mei-Yin Polley; Russell Pieper; Joseph F Costello; Scott Vandenberg; Rupa Parvataneni; Angelina Nicole; Patricia K Sneed; Jennifer Clarke; Emily Hsieh; Bruno M Costa; Rui M Reis; Maria Hristova-Kazmierski; Steven J Nicol; Donald E Thornton; Michael D Prados
Journal:  Neuro Oncol       Date:  2011-09-06       Impact factor: 12.300

6.  Measurement of tamoxifen-induced apoptosis in glioblastoma by cytometric bead analysis of active caspase-3.

Authors:  Joy K Zartman; Nicholas K Foreman; Andrew M Donson; Julie M Fleitz
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 7.  PKC signaling in glioblastoma.

Authors:  Anália do Carmo; Joana Balça-Silva; Diana Matias; Maria Celeste Lopes
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

8.  Dap160/intersectin binds and activates aPKC to regulate cell polarity and cell cycle progression.

Authors:  Chiswili Chabu; Chris Q Doe
Journal:  Development       Date:  2008-07-09       Impact factor: 6.868

9.  Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1.

Authors:  Ping Yi; Qin Feng; Larbi Amazit; David M Lonard; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Cell       Date:  2008-02-29       Impact factor: 17.970

Review 10.  Par complex in cancer: a regulator of normal cell polarity joins the dark side.

Authors:  V Aranda; M E Nolan; S K Muthuswamy
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.